Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
3.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
4.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582542
5.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063955
6.
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Haematologica
; 102(5): e203-e206, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28082342
7.
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Am J Hematol
; 92(9): E557-E559, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612372
8.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet
; 376(9758): 2075-85, 2010 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-21146205
9.
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Transplant Cell Ther
; 27(3): 244.e1-244.e8, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781522
10.
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Hum Vaccin Immunother
; 17(11): 4144-4154, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34406911
11.
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Lancet Haematol
; 8(2): e110-e121, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513372
12.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol
; 7(12): e861-e873, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242443
13.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer J
; 11(12): 197, 2021 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34876566
14.
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Blood Cancer J
; 10(5): 58, 2020 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424154
15.
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
Haematologica
; 89(7): 826-31, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15257934
16.
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
Leuk Lymphoma
; 45(7): 1419-28, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15359643
17.
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Mediterr J Hematol Infect Dis
; 5(1): e2013037, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23795275
18.
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
J Clin Oncol
; 29(8): 986-93, 2011 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21282540
19.
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Br J Haematol
; 139(3): 415-24, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17910631
20.
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
J Clin Oncol
; 25(17): 2434-41, 2007 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-17485707